Marketing and drug costs: Who is laughing and crying?

Annals of Neurology

Volumn 61, Issue 2, 2007, Pages

  Johnston, S Claiborne ^a   Hauser, Stephen L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; DEXTROMETHORPHAN; DEXTROMETHORPHAN PLUS QUINIDINE; IMIPRAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEURODEX; NORTRIPTYLINE; QUINIDINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; EDITORIAL; EMOTIONAL DISORDER; FOOD AND DRUG ADMINISTRATION; HEALTH CARE SYSTEM; HUMAN; PATHOLOGICAL CRYING; PATHOLOGICAL LAUGHTER; PRIORITY JOURNAL; PSEUDOBULBAR AFFECT; QUALITY OF LIFE; SYMPTOMATOLOGY; TREATMENT OUTCOME; UNITED STATES;

AFFECTIVE SYMPTOMS; DEXTROMETHORPHAN; DRUG COMBINATIONS; DRUG COSTS; DRUG INDUSTRY; HUMANS; LAUGHTER; MARKETING; QUINIDINE; SMILING;

EID: 33847666916     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21100     Document Type: Editorial

References (4)

1. Pollack A. Marketing a disease, and also a drug to treat it. New York Times, May 9, 2005. Available at: http://query.nytimes.com/gst/fullpage.html? sec=health&res=9400E4D61530F93AA35756 C0A9639C8B63. Accessed Jan 15, 2007.
2. Cummings JL, Arciniegas DB, Brooks BR, et al. Defining and diagnosing involuntary emotional expression disorder. CNS Spectrums 2006;11:1-7.
3. Panitch HS, Thisted RA, Smith RA, et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol 2006;59:780-787.
4. Rosen HJ, Cummings J. A real reason for patients with pseudobulbar affect to smile. Ann Neurol 2007;61:92-96.